Gandara-Loe, Jesus et al. published their research in ACS Applied Materials & Interfaces in 2019 | CAS: 70359-46-5

5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5) belongs to quinoxaline derivatives. Quinoxaline derivatives are important constituents of pharmacologically active compounds, including antibacterial, antibiotic and antineoplastic, antifungal, anti-inflammatory and analgesic drugs. Modifying quinoxaline structure it is possible to obtain a wide variety of biomedical applications, namely antimicrobial activities and chronic and metabolic diseases treatment.Recommanded Product: 70359-46-5

Metal-Organic Frameworks as Drug Delivery Platforms for Ocular Therapeutics was written by Gandara-Loe, Jesus;Ortuno-Lizaran, Isabel;Fernandez-Sanchez, Laura;Alio, Jorge L.;Cuenca, Nicolas;Vega-Estrada, Alfredo;Silvestre-Albero, Joaquin. And the article was included in ACS Applied Materials & Interfaces in 2019.Recommanded Product: 70359-46-5 This article mentions the following:

Metal-organic frameworks (MOFs) have been evaluated as potential nanocarriers for intraocular incorporation of brimonidine tartrate to treat chronic glaucoma. Exptl. results show that UiO-67 and MIL-100 (Fe) exhibit the highest loading capacity with values up to 50-60 weight %, whereas the performance is quite limited for MOFs with narrow cavities (below 0.8 nm, for example, UiO-66 and HKUST-1). The large loading capacity in UiO-67 is accompanied by an irreversible structural amorphization in aqueous and physiol. media that promotes extended release kinetics above 12 days. Compared to the traditional drawbacks associated with the sudden release of the com. drugs (e.g., ALPHAGAN), these results anticipate UiO-67 as a potential nanocarrier for drug delivery in intraocular therapeutics. These promising results are further supported by cytotoxicity tests using retinal photoreceptor cells (661W). Toxicity of these structures (including the metal nodes and organic ligands) for retinal cells is rather low for all samples evaluated, except for HKUST-1. In the experiment, the researchers used many compounds, for example, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5Recommanded Product: 70359-46-5).

5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5) belongs to quinoxaline derivatives. Quinoxaline derivatives are important constituents of pharmacologically active compounds, including antibacterial, antibiotic and antineoplastic, antifungal, anti-inflammatory and analgesic drugs. Modifying quinoxaline structure it is possible to obtain a wide variety of biomedical applications, namely antimicrobial activities and chronic and metabolic diseases treatment.Recommanded Product: 70359-46-5

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider